1 completed. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Completed 1 |
Follow LGX818: new trials by email Literature Review of LGX818 trials Research Report on LGX818
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma LGX818, MEK162, vemurafenib - Melanoma | Phase 3 | Completed | Pfizer | 921 | 2013-09-12 | 2026-02-27 |
Melanoma (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Skin Diseases (1) · Skin Neoplasms (1)
Pfizer (1)
Argentina (1) · Australia (1) · Brazil (1) · Canada (1) · Colombia (1) · Czechia (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · Israel (1) · Italy (1) · Japan (1) · Mexico (1) · Netherlands (1)
PMID 29573941, PMID 30219628, PMID 31437754, PMID 34091420, PMID 35862871, PMID 36653848, PMID 37309702, PMID 37506329, PMID 37534686